Ponsegromab remedy over 64 weeks resulted in sustained enhancements in physique weight and suppression of development differentiation issue 15 (GDF-15), a stress-induced cytokine, no matter prior remedy project, with a constant tolerable security profile, in keeping with data shared in a presentation on the
Sufferers initially randomized to placebo benefited from weight achieve upon transitioning to ponsegromab, though absolute positive factors had been decrease than these constantly handled, presenter Dr. Jeffrey Crawford emphasised through the presentation.
Crawford, a medical oncologist at Duke Most cancers Heart and Duke Most cancers Heart Thoracic Clinic in Durham, North Carolina, introduced the one-year open-label extension outcomes from the randomized section 2 examine evaluating ponsegromab in sufferers with cancer-associated cachexia, constructing on beforehand reported 12-week double-blind information.
“Enhancements in physique weight at week 12 … continued with ponsegromab by way of week 64 within the open-label extension,” defined Crawford to the viewers in Berlin. “Sufferers assigned to placebo in Half A confirmed an enchancment in physique weight through the open label extension, however total, their physique weight achieve was lower than what we noticed for sufferers who acquired ponsegromab all through the examine.”
What Is Most cancers-Related Cachexia and GDF-15’s Position
Cachexia stays a typical complication in oncology with no presently permitted pharmacologic therapies in the US or Europe. GDF-15 has been implicated in cachexia pathogenesis by way of its interplay with the GFRAL receptor within the hindbrain. Crawford defined that ponsegromab is a potent, extremely selective humanized monoclonal antibody that binds GDF-15, stopping its signaling by way of GFRAL.
Within the previous 12-week double-blind examine, ponsegromab demonstrated enhancements in physique weight, urge for food, cachexia-related signs, total bodily exercise and skeletal muscle mass versus placebo, with a good security profile. The present evaluation aimed to judge longitudinal modifications in physique weight, GDF-15 ranges, and security over a 64-week remedy interval.
Randomized Section 2 Ponsegromab Research Design: Half A and Half B
The trial comprised two components. Half A was a 12-week double-blind, randomized, placebo-controlled examine. Eligible sufferers included these with non-small cell lung most cancers, pancreatic most cancers, or colorectal most cancers assembly Fearon standards for cachexia, with elevated circulating GDF-15, ECOG efficiency standing 3 or much less, and life expectancy 4 months or extra.
Sufferers had been randomly assigned to obtain placebo or ponsegromab at 100 milligrams (mg), 200 mg, or 400 mg subcutaneously (by injection) each 4 weeks for 3 doses. The first endpoint of Half A was change in physique weight at week 12, with secondary endpoints together with patient-reported outcomes, bodily exercise, gait, security, and lumbar skeletal muscle index.
Half B consisted of a 52-week open-label extension by which all eligible sufferers acquired ponsegromab 400 mg subcutaneously each 4 weeks by way of week 64. Exploratory endpoints included modifications from baseline in physique weight, pharmacokinetics, circulating GDF-15 concentrations, immunogenicity, and security.
A complete of 281 sufferers had been screened, with 187 randomized to Half A, and 117 sufferers entered Half B.
Sustained Weight Achieve Noticed Throughout 64-Week Research of Ponsegromab
Noticed imply modifications from baseline in physique weight for Half B sufferers demonstrated progressive positive factors over the 52-week open-label extension. At week 12, reflecting Half A remedy project, the general imply enhance was 1.26 kilograms (kg), rising to five.18 kg at week 64, akin to a imply 9.35% enhance from baseline.
When stratified by Half A project, sufferers initially randomized to placebo skilled weight reduction at week 12 however gained weight following initiation of open-label ponsegromab 400 mg, albeit attaining much less total achieve than sufferers constantly handled with ponsegromab from Half A. Blended-model analyses corroborated these outcomes, demonstrating constant weight will increase throughout all Half B individuals.
“We be aware that the placebo group, throughout all these time factors, tends to achieve much less weight than the group initially assigned ponsegromab,” mentioned Crawford. “… We see a rise throughout all teams in weight with open-label ponsegromab 400 mg, however the preliminary placebo group lags behind.”
GDF-15 suppression was sturdy and sustained. At week 12, placebo sufferers demonstrated rising GDF-15 ranges, whereas ponsegromab-treated teams (100 mg-400 mg) exhibited 55% to 97% reductions. After transitioning to open-label ponsegromab 400 mg, all sufferers achieved a median 97% lower in GDF-15, maintained by way of week 64, no matter preliminary remedy.
Security Profile: Ponsegromab Properly-Tolerated With Minimal Therapy-Associated Facet Results
Uncomfortable side effects had been frequent (84.2%), largely pushed by underlying malignancy, concomitant therapies, and comorbidities, in keeping with Crawford. Grade 1 to 2 uncomfortable side effects occurred in 34.2%, grade 3 to 4 in 29.8%, and grade 5 (dying) in 20.2% of sufferers.
Severe uncomfortable side effects affected 43.9%, with 24.6% completely discontinuing examine interventions. Importantly, treatment-related uncomfortable side effects had been uncommon (lower than 5%) and restricted to grade 1-2; no deaths had been thought-about associated to ponsegromab.
Subsequent Steps: Section 2b Research in Metastatic Pancreatic Most cancers
These outcomes assist ongoing analysis within the section 2b examine of ponsegromab in sufferers with metastatic pancreatic most cancers receiving first-line chemotherapy, designed to outline optimum dosing for a subsequent pivotal section 3 trial, incorporating each cachexia-specific and treatment-related outcomes.
Reference
- “Efficacy and security of ponsegromab in sufferers with cancer-associated cachexia: Outcomes from the open-label extension of a randomized, placebo-controlled,” by Dr. Jeffrey Crawford. Introduced at: ESMO 2025 Congress; October 17-21, 2025; Berlin, Germany. Summary LBA102.
For extra information on most cancers updates, analysis and training,
